Thrombolytic Therapy for Acute Ischemic Stroke: Past and Future

Area of Science:

• Neurology
• Cardiovascular Medicine
• Pharmacology

Background:

• Ischemic stroke, a leading cause of death, is often linked to hypertension, dyslipidemia, atrial fibrillation, and diabetes.
• Thrombolytic therapy, developed to dissolve blood clots, has a history dating back to the 1950s.
• Current treatments face limitations due to potential hemorrhagic complications, necessitating a defined therapeutic time window.

Purpose of the Study:

• To provide a comprehensive overview of the pathophysiology of ischemic stroke.
• To trace the historical development of thrombolytic therapies.
• To discuss recent advancements in thrombolytic drug development.

Main Methods:

• Literature review and synthesis of existing research on ischemic stroke.
• Historical analysis of thrombolytic therapy evolution.
• Discussion of current and emerging thrombolytic drug research.

Main Results:

• Ischemic stroke pathophysiology involves complex mechanisms often exacerbated by common chronic conditions.
• The evolution of thrombolytic therapy shows a progression from early trials to modern drug development.
• Significant efforts are underway to create next-generation thrombolytic agents.

Conclusions:

• Thrombolytic therapy, while effective, carries risks such as hemorrhage, limiting its safe application window.
• Continued research into novel thrombolytic drugs is crucial for expanding treatment options and improving patient outcomes.
• Developing safer and more effective thrombolytic agents is a key goal for future stroke management.